Literature DB >> 29157381

Lung Neoplasms with Low F18-Fluorodeoxyglucose Avidity.

Yiyan Liu1.   

Abstract

Some malignant lung neoplasms may demonstrate low or absent uptake on F18-fluorodeoxyglucose (FDG) PET/computed tomography. Pathologic type and clinical stage are independent factors associated with FDG avidity. Among lung malignancies with low FDG avidity, adenocarcinoma in situ and carcinoid are the most common. Early stage disease often has low FDG uptake. Small lesion size is another significant factor associated with negative FDG PET findings, which is due to a partial volume effect. Morphology of lung lesions on anatomic images may also affect FDG avidity. Subsolid pulmonary nodules, ground-glass nodules, or ground-glass opacity may be sources of false-negative PET.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  FDG PET/CT; FDG avidity; FDG uptake; Lung cancer

Mesh:

Substances:

Year:  2017        PMID: 29157381     DOI: 10.1016/j.cpet.2017.08.002

Source DB:  PubMed          Journal:  PET Clin        ISSN: 1556-8598


  4 in total

Review 1.  The role of positron emission tomography in the diagnosis, staging and response assessment of non-small cell lung cancer.

Authors:  Sara Volpi; Jason M Ali; Angela Tasker; Adam Peryt; Giuseppe Aresu; Aman S Coonar
Journal:  Ann Transl Med       Date:  2018-03

2.  Contribution of 18F-FDG PET/CT in the Differential Diagnosis of Pulmonary Hamartomas and Pulmonary Carcinoids

Authors:  Ebru Tatcı; Özlem Özmen; Ayperi Öztürk; Funda Demirağ
Journal:  Mol Imaging Radionucl Ther       Date:  2021-06-03

3.  The Contribution of Fluorine 18F-FDG PET/CT to Lung Cancer Diagnosis, Staging and Treatment Planning.

Authors:  Emine Budak; Gürsel Çok; Ayşegül Akgün
Journal:  Mol Imaging Radionucl Ther       Date:  2018-06-07

4.  A Pilot Study of Radiomics Models Combining Multi-Probe and Multi-Modality Images of 68Ga-NOTA-PRGD2 and 18F-FDG PET/CT for Differentiating Benign and Malignant Pulmonary Space-Occupying Lesions.

Authors:  Fei Xie; Kun Zheng; Linwen Liu; Xiaona Jin; Lilan Fu; Zhaohui Zhu
Journal:  Front Oncol       Date:  2022-06-02       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.